...
首页> 外文期刊>Pediatric Hematology and Oncology >Current Management of the Hemophilic Child: A Demanding Interlocutor. Quality of Life and Adequate Cost-Efficacy Analysis
【24h】

Current Management of the Hemophilic Child: A Demanding Interlocutor. Quality of Life and Adequate Cost-Efficacy Analysis

机译:血友病儿童的当前管理:一位苛刻的对话者。生活质量和足够的成本效益分析

获取原文
获取原文并翻译 | 示例
           

摘要

Hemophilias are the most known inherited bleeding disorders. The challenges in the management of hemophilic children are different from those in adults: prophylaxis regimen removed the hallmark of crippling disease with lifelong disabilities; individualized regimens are being implemented in order to overcome venous access problems. Presently, at least in high-income countries, advances in treatment of hemophilia resulted in continuous improvement of the patients' quality of life and life expectancy. Inhibitors remain the most severe complication of hemophilia therapy. The treatment' compliance is the key to achieve a successful management. The patient, his family, the medical and psychological team are the players of a comprehensive care system. The current management of hemophilic children is the example of huge resource investments enabling long-term benefits in particular quality of life as a primary objective of the healthcare process.
机译:血友病是最著名的遗传性出血病。血友病儿童的管理挑战与成人挑战不同:预防方案消除了终身残疾致残性疾病的标志;为了克服静脉通路问题,正在实施个性化的治疗方案。目前,至少在高收入国家,血友病治疗的进步导致患者的生活质量和预期寿命不断提高。抑制剂仍然是血友病治疗最严重的并发症。治疗的依从性是实现成功管理的关键。患者,他的家人,医疗和心理团队是全面护理系统的参与者。血友病儿童的当前管理就是大量资源投资的示例,它使长期受益,特别是生活质量成为医疗保健过程的主要目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号